文献速递乳腺癌

早期三阴性乳腺癌标准化疗后辅助卡培他滨的III期试验

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
PubMed 文献 · J Clin Oncol · 2019-12-05

GEICAM/2003-11_CIBOMA/2004-01 III期试验纳入可手术早期三阴性乳腺癌患者,在完成含蒽环类和/或紫杉类标准化疗后随机接受卡培他滨或观察。预设亚组分析提示非基底样表型患者可能获益,但需进一步验证。

要点

  • 标准化疗后延长辅助卡培他滨未显著改善早期TNBC的无病生存期。
  • 预设亚组中非基底样表型患者加用卡培他滨的DFS HR为0.53,基底样为0.94。
  • 卡培他滨耐受性符合预期,75.2%患者完成计划的8个周期。

核心结论

  • 在早期三阴性乳腺癌患者中,标准化疗后延长辅助卡培他滨未能显著提高无病生存期。
  • 预设亚组分析提示非基底样表型患者可能从卡培他滨中获益,但需额外验证。

研究设计与样本

  • III期随机对照试验,纳入可手术、淋巴结阳性或淋巴结阴性且肿瘤≥1 cm的早期TNBC患者。
  • 患者既往接受含蒽环类和/或紫杉类化疗,按机构、既往紫杉类治疗、腋窝淋巴结受累及中心确定表型分层。
  • 中位年龄49岁,55.9%淋巴结阴性,73.9%为基底样表型,67.5%既往接受蒽环类联合紫杉类。
  • 中位随访7.3年。

主要发现

  • 卡培他滨耐受性符合预期,75.2%患者完成计划的8个周期。

关键数值与推荐

  • 75.2%的患者完成计划的8个周期卡培他滨治疗。

临床怎么用

  • 不推荐在早期TNBC标准化疗后常规延长辅助卡培他滨。
  • 非基底样表型患者可能从卡培他滨中获益,但需进一步验证后才能用于临床决策。

局限性

  • 非基底样表型的获益发现需额外验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy in patients with early TNBC. PATIENTS AND METHODS: Eligible patients were those with operable, node-positive-or node negative with tumor 1 cm or greater-TNBC, with prior anthracycline- and/or taxane-containing chemotherapy. After central confirmation of TNBC status by immunohistochemistry, patients were randomly assigned to either capecitabine or observation. Stratification factors included institution, prior taxane-based therapy, involved axillary lymph nodes, and centrally determined phenotype (basal v nonbasal, according to cytokeratins 5/6 and/or epidermal growth factor receptor positivity by immunohistochemistry). The primary objective was to compare disease-free survival (DFS) between both arms. RESULTS: Eight hundred seventy-six patients were randomly assigned to capecitabine (n = 448) or observation (n = 428). Median age was 49 years, 55.9% were lymph node negative, 73.9% had a basal phenotype, and 67.5% received previous anthracyclines plus taxanes. Median length of follow-up was 7.3 years. DFS was not significantly prolonged with capecitabine versus observation [hazard ratio (HR), 0.82; 95% CI, 0.63 to 1.06; P = .136]. In a preplanned subgroup analysis, nonbasal patients seemed to derive benefit from the addition of capecitabine with a DFS HR of 0.53 versus 0.94 in those with basal phenotype (interaction test P = .0694) and an HR for overall survival of 0.42 versus 1.23 in basal phenotype (interaction test P = .0052). Tolerance of capecitabine was as expected, with 75.2% of patients completing the planned 8 cycles. CONCLUSION: This study failed to show a statistically significant increase in DFS by adding extended capecitabine to standard chemotherapy in patients with early TNBC. In a preplanned subset analysis, patients with nonbasal phenotype seemed to obtain benefit with capecitabine, although this will require additional validation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lluch A, Barrios CH, Torrecillas L, et al. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2019. PMID: 31804894. doi:10.1200/JCO.19.00904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。